One of the newest, most promising treatments for blood cancer is chimeric antigen receptor (CAR)-T cell therapy. These therapies use your body's own immune system to help fight cancer. The CAR-T cells are manufactured from patient T-cells, which are genetically altered by using Lentiviral vectors. Janssen Biologics is constructing a manufacturing site for Lentiviral vector in Sassenheim to support the global Janssen Supply Chain. A new plant in and existing building with a new process using state of the art equipment. This presentation will give an insight in the design, construction and the manufacturing process of lentiviral vectors.